Volume 4, Issue 2

New ART Agents: A Clinical Perspective

In this issue:

Recently approved treatment options and new antiviral therapies still under investigation — through case-based discussion, Dr. Ethel Weld from the Division of Clinical Pharmacology and Infectious Diseases at the Johns Hopkins University School of Medicine explains how the promise of these new agents can impact current clinical practice.

Learning objectives:

  • Discuss the potential clinical use of the coformulation of BIC/TAF/FTC (bictegravir/tenofovir alafenamide/ emtricitabine) as compared to other options.
  • Describe switching regimens for virologically suppressed patients, and the potential role of duotherapy with DTG/RPV (dolutegravir and rilpivirine) in the treatment of HIV.
  • Identify those patients in whom the clinical use of ibalizumab can be considered.

Author:

Ethel D. Weld, MD
Ethel D. Weld, MD
Assistant Professor of Medicine, Pharmacology, & Molecular Sciences
Division of Clinical Pharmacology & Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Program Directors:

Allison L. Agwu, MD, ScM, FAAP, FIDSA
Associate Professor of Pediatrics and Adult Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Alysse G. Wurcel, MD, MS
Assistant Professor
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
Boston, Massachusetts

Justin Alves, RN, ACRN, CARN
Infectious Disease Associates
Massachusetts General Hospital
Boston, Massachusetts

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: September 27, 2018
Expiration date: September 26, 2020

Sign-In

Not a subscriber? Start here!